Top

Our ongoing
commitment.

Produce Humacyte’s life-sustaining, human, bioengineered HAV
designed to become the patient’s own and integrate naturally for
patients who need a better clinical alternative for vascular access.

What matters to us.

We are committed to becoming the leader in novel, human acellular matrix products for vascular and non-vascular applications. These products are engineered to be immediately available and can have the potential to improve efficacy, safety, and treatment outcomes in patients with a broad range of disease conditions.

Our goal is to develop and commercialize our products in the US, and potentially license commercialization rights in ex-US markets. Our corresponding product development strategy aims for the fastest speed to market by pursuing approval for indications with the greatest chance of clinical success and safety, through well-established regulatory pathways for approval.

Humacyte is a privately-held company that was founded in 2004 by
Laura Niklason, MD. PhD., a world leader in tissue engineering, and currently Professor of Biomedical Engineering and Anesthesia at Yale University. Niklason co- founded Humacyte along with Drs. Shannon Dahl and Juliana Blum. Humacyte’s research platforms and core technologies are based on the research conducted by Drs. Niklason and Dahl at Duke University, and by Dr. Niklason at the Massachusetts Institute of Technology in the laboratory of Dr. Robert Langer.

Our team of senior management advisors and board of directors have extensive, proven experience in product development, clinical trials, regulatory affairs, business and commercial development, finance and intellectual property management.

READ MORE

Our goal is to develop and commercialize our products in the US, and potentially license commercialization rights in ex-US markets. Our corresponding product development strategy aims for the fastest speed to market by pursuing approval for indications with the greatest chance of clinical success and safety, through well-established regulatory pathways for approval.

Humacyte is a privately-held company that was founded in 2004 by Laura Niklason, MD. PhD., a world leader in tissue engineering, and currently Professor of Biomedical Engineering and Anesthesia at Yale University. Niklason co- founded Humacyte along with Drs. Shannon Dahl and Juliana Blum. Humacyte’s research platforms and core technologies are based on the research conducted by Drs. Niklason and Dahl at Duke University, and by Dr. Niklason at the Massachusetts Institute of Technology in the laboratory of Dr. Robert Langer.

Our team of senior management advisors and board of directors have extensive, proven experience in product development, clinical trials, regulatory affairs, business and commercial development, finance and intellectual property management.

See how far
we’ve come.

We’re proud of the steps we’ve taken
and the progress we’ve made.

June 7, 2016

Humacyte wins
2016
CNBC Disruptor Award

In the fourth annual Disruptor 50 list, CNBC features
private companies in 15 industries — from aerospace to
financial services to cybersecurity to retail — whose
innovations are revolutionizing the business landscape.
Humacyte is pleased to be included along side companies
like Uber, Airbnb, and 23andMe.

November 17, 2015

Humacyte presents at
42nd Annual Symposium on
Vascular and Endovascular Issues

Humacyte’s Jeffrey H. Lawson, M.D., Ph.D., presented
three sessions at the leading vascular specialist conference,
the VEITH symposium. Dr. Lawson’s presentations focused
on new techniques in human tissue engineered arterial
vascular access conduits and how to optimize outcomes
in hemodialysis access.

November 9, 2015

Humacyte appears at American
Heart Association Scientific Sessions

Humacyte’s founder, Laura Niklason, M.D., Ph.D.,
addressed the American Heart Association (AHA) in
its Scientific Sessions. Dr. Niklason delivered a
presentation titled “Bioengineered Arteries for
Peripheral Bypass: Early Clinical Experience” at
this conference, one of the leading cardiovascular
meetings in the country.

October 20, 2015

Company Founder Elected to
National Academy of Medicine

The Humacyte team was proud to celebrate its founder,
Laura Niklason, M.D., Ph.D., being elected to the prestigious
National Academy of Medicine (NAM) for her lifelong
contributions to medical advancement and research in
regenerative medicine and technology.

October 5, 2015

Humacyte names new
Chief Medical Officer

Humacyte was proud to appoint American Board of Surgery
certified surgeon Jeffrey H. Lawson, M.D., Ph.D., as its
Chief Medical Officer. After serving as a clinical advisor
to Humacyte over the past 10 years, Dr. Lawson’s new role
had him oversee the medical and clinical development of
the Company’s products.

September 8, 2015

Humacyte delivers
keynote addresses at TERMIS

Humacyte’s Laura Niklason, M.D., Ph.D., and Robert Langer,
Ph.D., delivered two keynote addresses (“Platforms and
Complexity in Tissue and Organ Regeneration” and “Biomaterials
and Tissue Engineering”, respectively) at the 4th TERMIS World
Congress. This event, held every three years, brings together
researchers, scientists, trainees, and students from academia
and healthcare to discuss critical developments in
regenerative medicine.

September 2, 2015

New Additions to
Humacyte’s Board of Directors

Humacyte was proud to add former U.S. Secretary of Health
and Human Services Kathleen Sebelius and healthcare executive
Dale A. Sander to our Board of Directors. These new members
increased the size of the Humacyte Board to eight directors,
and set up Humacyte for exciting developments through our
next phase of growth.

May 14, 2015

Humacyte VASA
Practicum Presentation

Humacyte’s Jeffrey H. Lawson, M.D., Ph.D., presented at
the 2015 Vascular Access Society of the Americas (VASA)
Practicum at Duke University Medical Center in Durham, NC.
His presentation “Tissue Engineering of Vascular Access
Grafts” discussed Humacyte’s Humacyl™, a human acellular
vessel that is being developed for key applications in
regenerative medicine and vascular surgery.

March 2, 2015

North Carolina Excellence
Award goes to Humacyte

Humacyte was proud to add former U.S. Secretary of Health
and Human Services Kathleen Sebelius and healthcare executive
Dale A. Sander to our Board of Directors. These new members
increased the size of the Humacyte Board to eight directors,
and set up Humacyte for exciting developments through our
next phase of growth.

January 31, 2015

The 27th International Symposium
on Endovascular Therapy (ISET)
welcomes Humacyte

Humacyte’s Jeffrey H. Lawson, M.D., Ph.D., served as the
keynote speaker at the 27th International Symposium on
Endovascular Therapy. Dr. Lawson’s keynote “Bioengineering
and the Potential to Create New Blood Vessels” was
well-received by thought leaders from around the world.

July 23, 2014

Humacyte Receives Fast
Track Designation for HUMACYL
welcomes Humacyte

Humacyte, Inc., has announced that the U.S. Food and Drug
Administration (FDA) has designated the HUMACYL development
program for vascular access in hemodialysis patients as
a Fast Track Development Program.

June 24, 2014

Humacyte Announces Competition
of Enrollment for Studies of
Bioengineered Blood Vessel

Humacyte, Inc. has announced the completion of patient
enrollment for two multi-center, investigative studies
to assess the safety and efficacy of its bioengineered
blood vessel in patients with End Stage Renal Disease (ESRD).

December 12, 2013

Dr. Laura Niklason, M.D., PhD.
elected to rank of NAI Fellow

The National Academy of Inventors Fellows Selection
Committee announced the election of Dr. Laura Niklason, M.D., PhD.,
Founder of Humacyte, to the rank of NAI Fellow. NAI Fellows
are chosen for having demonstrated a highly prolific spirit
of innovation in creating or facilitating outstanding
inventions that have made a tangible impact on quality
of life, economic development, and the welfare of society.

October 20, 2013

Humacyte technology featured
at The Controversies in
Dialysis Access Meeting

Dr Jeffrey Lawson presents The Future of AVG at The
Controversies in Dialysis Access (CiDA) Meeting, San Francisco,
and features Humacyte investigational bioengineered
blood vessel.

October 10, 2013

Humacyte receives 2013
North Carolina Excellence Award

Humacyte was awarded the 2013 North Carolina Exellence
Award from the Small Business Institute for Excellence
in Commerce (SBIEC).

October 4, 2013

Humacyte enters into
long-term manufacturing partnership

Humacyte enters into a long-term strategic manufacturing
partnership with AlloSource to create the investigational
bioengineered blood vessels being developed for hemodialysis
applications.

June 1, 2013

Humacyte begins US Arterio-Venous
Clinical Phase ½ Study

US Arterio-Venous Clinical Phase 1/2 Study begins as
surgeons at perform first US implant of Humacyte investigational
bioengineered blood vessel graft in arm of kidney
dialysis patient.

April 26, 2013

Humacyte begins Phase ½
Multi-Center Clinical Trial

US Arterio-Venous Clinical Phase 1/2 Study begins as
surgeons at perform first US implant of Humacyte investigational
bioengineered blood vessel graft in arm of kidney dialysis patient.

April 20, 2013

Humacyte’s preclinical data presented
at Vascular Access Society Meeting

Dr. Jeffrey Lawson presents preclinical data at Vascular
Access Society Meeting in Prague suggesting the potential
benefits of Humacyte’s technology

April 5, 2013

Poland AV trial affirms Humacyte’s
investigational blood vessel safety

EU Safety Committee determined that the trial enrollment
of Humacyte investigational bioengineered blood vessel
could continue in Poland arterio-venous (AV) vascular access trial.

April 1, 2013

Humacyte presents preclinical data
at American Heart Association’s
Emerging Science Series

Dr. Shannon Dahl presents preclinical data at American
Heart Association’s Emerging Science Series suggesting the
potential for “off-the-shelf” blood vessels that could one
day reduce some complications of dialysis treatment.

December 1, 2012

Humacyte Pilot Study
begins in Europe

Phase ½ Multi-Center Pilot Study of the Humacyte investigational
bioengineered blood vessel begins in Europe.

March 1, 2012

Fast Company names Humacyte
as one of the “Top 50 World’s
Most Innovative Companies”

Fast Company praises Humacyte’s technological advances,
highlighting the ability to grow blood vessels from scratch.
[Read the Article]

October 1, 2011

Popular Mechanics recognizes
Humacyte technology as
“Breakthrough Innovation of 2011”

Popular Mechanics recognized Humacyte investigational
bioengineered blood vessel Technology as a “Breakthrough
Innovation of 2011”. This technology is under clinical
study by Humacyte, and Humacyte plans to seek FDA approval
of the technology.
[Read the Article]

September 1, 2011

Humacyte Receives Frost & Sullivan
Award for New Product Innovation

Humacyte Receives Frost & Sullivan Award for New
Product Innovation

Febuary 5, 2011

Humacyte data published
in Science Transitional Medicine

Access the paper by registering on the website, here.
[Read the Article]

    Industry Visionaries
    and Healthcare
    Executives

    Our leadership team is focused on
    developing a novel platform
    technology to shape human tissues

    to be used for hemodialysis and the
    treatment of vascular diseases.

    Board of Directors

    Robert Anderson, M.D.
    Cardiac Surgeon, former Chief of Surgery at Duke University, and a Key Opinion leader in cardiovascular surgery

    Carrie S. Cox
    Former Chairman Prism Pharmaceuticals, EVP and President, Global Pharmaceuticals at Schering Plough Corporation, President, Global Prescription Business at Pharmacia Corporation

    Brady W. Dougan
    Former CEO of Credit-Suisse

    Robert Langer, Sc.D.
    David Koch Institute Professor at Massachusetts Institute of Technology, and a world leader in tissue engineering and regenerative medicine

    Laura Niklason, M.D., Ph.D.
    Humacyte Founder, Nicholas Greene Professor of Anesthesiology and Professor of Biomedical Engineering, Vice-Chair for Anesthesia at Yale, and world leader in cellular therapies and regenerative medicine.

    Dale A. Sander
    Senior Vice President, Global Accounting Officer at Sutherland Global Services, Inc., Former Chief Financial Officer role at Biolex Therapeutics and leadership positions at life science companies Maxim Pharmaceuticals, Inc., Xytronyx, Inc., and Tactyl Technologies, Inc.

    Honorable Kathleen Sebelius
    Former 21st Secretary of the Department of Health and Human Services (HHS). Former Governor of Kansas, served two terms as the Kansas insurance commissioner, and four terms in the Kansas Legislature.

    Max Wallace, J.D.
    Former CEO of Cogent Neurosciences, former CEO of Trimeris, and currently heads Accelerate Brain Cancer Cure, a private foundation

    Humacyte’s
    state-of-the–art
    facilities
    reflect a
    continuing
    commitment to the

    quality of our
    products.

    Our new state-of-the–art cGMP manufacturing facility is located at 2525
    Highway 54 in Durham, NC. The new facility will also be home to our R&D and
    administration capabilities.

    We’re building
    strong relationships
    with
    our growing family of partners.

    We’re proud of our research and
    manufacturing partners and
    honored that
    they stand with us on
    our commitment to lifesaving
    possibilities.

    INTERESTED IN PARTNERING WITH US?
    We’d love to hear from you.